FFA
KLRS

Farther Finance Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Farther Finance Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33
Closed -$191 – 5633
2025
Q3 		$191 Hold
33
– – ﹤0.01% 4727
2025
Q2 		$88 Hold
33
– – ﹤0.01% 4324
2025
Q1 		$264 Hold
33
– – ﹤0.01% 3902
2024
Q4 		$323 Sell
33
-4
-11% -$61 ﹤0.01% 3538
2024
Q3 		$697 Hold
37
– – ﹤0.01% 3343
2024
Q2 		$629 Buy
37
+33
+825% +$583 ﹤0.01% 3218
2024
Q1 		$75 Buy
+4
New +$65 ﹤0.01% 3419

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Farther Finance Advisors's KLRS Position: Q4 2025 in Review

Farther Finance Advisors sold out of Kalaris Therapeutics (KLRS) in Q4 2025, closing a stake of 33 shares — an estimated $191 sold.

Farther Finance Advisors first reported a position in KLRS in Q1 2024 and held it in 7 quarters. The position peaked at $697 in Q3 2024. 51 funds tracked by Wall St. Rank hold KLRS as of Q4 2025.

  • Farther Finance Advisors reported no remaining Kalaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 33 Kalaris Therapeutics shares in Q4 2025, an estimated $191.
  • Farther Finance Advisors first reported a position in Kalaris Therapeutics in Q1 2024 and held it in 7 quarters.
  • Farther Finance Advisors's Kalaris Therapeutics position peaked at $697 in Q3 2024.
  • 51 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2025.

Based on Farther Finance Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.